<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="1" ids="50694">Minocycline</z:chebi>, a second-generation <z:chebi fb="9" ids="27902">tetracycline</z:chebi> with anti-inflammatory and anti-apoptotic properties, has been shown to promote therapeutic benefits in experimental <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>However, equally compelling evidence demonstrates that the drug exerts variable and even detrimental effects in many <z:e sem="disease" ids="C0027765" disease_type="Disease or Syndrome" abbrv="">neurological disease</z:e> models </plain></SENT>
<SENT sid="2" pm="."><plain>Assessment of the mechanism underlying <z:chebi fb="1" ids="50694">minocycline</z:chebi> neuroprotection should clarify the drug's clinical value in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> setting </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Here, we demonstrate that <z:chebi fb="1" ids="50694">minocycline</z:chebi> attenuates both in vitro (oxygen <z:chebi fb="105" ids="17234">glucose</z:chebi> deprivation) and in vivo (middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>) experimentally induced ischemic deficits by direct inhibition of apoptotic-like neuronal cell <z:hpo ids='HP_0011420'>death</z:hpo> involving the anti-apoptotic Bcl-2/<z:chebi fb="1" ids="18070">cytochrome c</z:chebi> pathway </plain></SENT>
<SENT sid="4" pm="."><plain>Such anti-apoptotic effect of <z:chebi fb="1" ids="50694">minocycline</z:chebi> is seen in neurons, but not apparent in astrocytes </plain></SENT>
<SENT sid="5" pm="."><plain>Our data further indicate that the neuroprotection is dose-dependent, in that only low dose <z:chebi fb="1" ids="50694">minocycline</z:chebi> inhibits neuronal cell <z:hpo ids='HP_0011420'>death</z:hpo> cascades at the <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> phase, whereas the high dose exacerbates the ischemic injury </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: The present study advises our community to proceed with caution to use the minimally invasive intravenous delivery of low dose <z:chebi fb="1" ids="50694">minocycline</z:chebi> in order to afford neuroprotection that is safe for <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>